Back to Results
First PageMeta Content
Clinical pharmacology / Drug discovery / Pharmaceutical industry / Peptide / Jerini / Pharmaceutical sciences / Pharmacology / Pharmacy


Phylogica enters transaction with UK biotech to identify and develop small molecule cancer drugs • • • •
Add to Reading List

Document Date: 2015-04-06 21:45:15

Open Document

File Size: 79,46 KB

Share Result on Facebook

City

Perth / Philadelphia / /

Company

Fox Chase / PhoreMost Limited / Cubist Pharmaceuticals / PhoreMost Phylogica / Genentech / Pfizer / MedImmune / Phylogica Limited / Cambridge UK / Horizon Discovery / Janssen / London Stock Exchange / /

Country

United States / Australia / United Kingdom / /

Currency

GBP / /

/

Event

IPO / Business Partnership / /

Facility

University of Cambridge / Telethon Kids Institute / Fox Chase Cancer Centre / /

/

IndustryTerm

biotechnology / pharmaceutical industry / cancer therapy / pharmaceutical / technology asset / bio-pharmaceutical / therapeutics for cancer / recombinant manufacturing processes / /

MedicalCondition

difficult diseases / novel cancer / heart disease / associated disease / intracellular disease / next-generation cancer / cancer / novel disease / small molecule cancer / diseases / infectious diseases / human disease / /

MedicalTreatment

small molecule therapies / cancer therapy / /

Organization

Fox Chase Cancer Centre / University of Cambridge / Telethon Kids Institute / /

Person

Venkitaraman / Chris Torrance / Richard Hopkins / Rudi Michelson / /

/

Position

founder / CEO / Professor / /

Product

Phylomer / /

Region

Western Australia / /

Technology

genomics / biotechnology / human genome / drug discovery / treating cancer / /

URL

www.phylogica.com / /

SocialTag